Recent Updates
Recently added Catalysts
SCNI Positive Sentiment

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Scinai Immunotherapeutics Ltd. has released its corporate highlights and financial results for the first half of 2026. The company is focusing on its growing contract development and manufacturing organization (CDMO) segment. An investor webinar is set for August 26, 2026, to discuss these developments further.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scinai reported strong corporate highlights for the first half of 2026.
  • The company is experiencing growing momentum in its CDMO segment.
  • An investor webinar is scheduled, indicating proactive communication with stakeholders.

Full Press Release Details

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT
JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.

Corporate Highlights

Frequently Asked Questions

What are the key highlights from Scinai's 2026 report?

Scinai reported strong corporate highlights and financial results for the first half of 2026.

When is Scinai's investor webinar scheduled?

The investor webinar is scheduled for August 26, 2026, at 11:00 a.m. EDT.

What focus area is Scinai emphasizing in 2026?

Scinai is emphasizing the growth of its contract development and manufacturing organization (CDMO).

ShareAdd on Google
Tags: SCNI Viatris Investor Conferences Healthcare Scinai Immunotherapeutics CDMO biopharmaceutical financial results investor webinar
Last updated: Aug 24, 2026

Biotech snapshot

Cash runway
$11M liquidity · $1M/mo burn
~0 mo
High dilution risk